Qlaris Bio, Inc.

Biotechnology ResearchUnited States2-10 Employees

Our lead asset, QLS-111, has a unique mechanism of action designed to lower intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the trabecular meshwork, thereby reducing distal outflow resistance and lowering EVP.

By reducing EVP and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.

QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.

Sign up for free to view info

Email Format Employee directory